More than 12 years’ medical writing experience in:
Oncology
– Non-small cell lung cancer
– Squamous cell carcinoma of the head & neck
– Cervical cancer
– Melanoma
Neuroscience
Real world evidence and HEOR
CMPP certification through ISMPP
Selected publications:
Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck.
Gastman BR, Zager JS, Messina JL, Cook RW, Covington KR, Middlebrook B, Gerami P, Wayne JD, Leachman S, Vetto JT.
Head Neck. 2019 Apr;41(4):871-879.
Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS, Gastman BR, Leachman S, Gonzalez RC, Fleming MD, Ferris LK, Ho J, Miller AR, Cook RW, Covington KR, Meldi-Plasseraud K, Middlebrook B, Kaminester LH, Greisinger A, Estrada SI, Pariser DM, Cranmer LD, Messina JL, Vetto JT, Wayne JD, Delman KA, Lawson DH, Gerami P.
BMC Cancer. 2018 Feb 5;18(1):130.
Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients.
Cook RW, Middlebrook B, Wilkinson J, Covington KR, Oelschlager K, Monzon FA, Stone JF.
Diagn Pathol. 2018 Feb 13;13(1):13.
Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK, Farberg AS, Middlebrook B, Johnson CE, Lassen N, Oelschlager KM, Maetzold DJ, Cook RW, Rigel DS, Gerami P.
J Am Acad Dermatol. 2017 May;76(5):818-825.e3.
Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test in a Prospective Multicenter Study.
Plasseraud KM, Cook RW, Tsai T, Shildkrot Y, Middlebrook B, Maetzold D, Wilkinson J, Stone J, Johnson C, Oelschlager K, Aaberg TM.
J Oncol. 2016;2016:5325762.